| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Eplerenone in patients with systolic heart failure and mild symptoms.
|
N Engl J Med
|
2010
|
14.43
|
|
2
|
Contribution of SHANK3 mutations to autism spectrum disorder.
|
Am J Hum Genet
|
2007
|
5.04
|
|
3
|
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
|
J Am Coll Cardiol
|
2005
|
3.53
|
|
4
|
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
|
J Am Coll Cardiol
|
2013
|
1.83
|
|
5
|
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.
|
J Am Coll Cardiol
|
2012
|
1.71
|
|
6
|
CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans.
|
J Lipid Res
|
2003
|
1.59
|
|
7
|
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
|
Circulation
|
2009
|
1.16
|
|
8
|
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
|
Clin Cancer Res
|
2010
|
1.10
|
|
9
|
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
|
Circulation
|
2012
|
1.06
|
|
10
|
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
|
Eur J Heart Fail
|
2010
|
1.02
|
|
11
|
Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age.
|
Eur J Heart Fail
|
2010
|
0.99
|
|
12
|
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
|
Circ Heart Fail
|
2013
|
0.96
|
|
13
|
Centromere protein A dynamics in human pluripotent stem cell self-renewal, differentiation and DNA damage.
|
Hum Mol Genet
|
2010
|
0.86
|
|
14
|
Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography.
|
Clin Microbiol Infect
|
1997
|
0.85
|
|
15
|
The Bipolar Association Case-Control Study (BACCS) and meta-analysis: No association with the 5,10-Methylenetetrahydrofolate reductase gene and bipolar disorder.
|
Am J Med Genet B Neuropsychiatr Genet
|
2010
|
0.84
|
|
16
|
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
|
Eur J Heart Fail
|
2012
|
0.82
|
|
17
|
Influence of range of motion in resistance training in women: early phase adaptations.
|
J Strength Cond Res
|
2005
|
0.82
|
|
18
|
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
|
Eur J Heart Fail
|
2009
|
0.81
|
|
19
|
Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial.
|
Int J Gen Med
|
2013
|
0.79
|
|
20
|
In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase.
|
Drug Metab Dispos
|
2010
|
0.78
|
|
21
|
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
|
Eur Heart J
|
2013
|
0.78
|
|
22
|
Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography.
|
Clin Microbiol Infect
|
1997
|
0.76
|
|
23
|
An analysis of full range of motion vs. partial range of motion training in the development of strength in untrained men.
|
J Strength Cond Res
|
2004
|
0.76
|
|
24
|
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
|
Circ Heart Fail
|
2013
|
0.75
|
|
25
|
Homophobic and sexist yet uncontested: examining football fan postings on Internet message boards.
|
J Homosex
|
2011
|
0.75
|
|
26
|
A job analysis of major college female strength and conditioning coaches.
|
J Strength Cond Res
|
2013
|
0.75
|
|
27
|
Job analysis of college Division I-A football strength and conditioning coaches.
|
J Strength Cond Res
|
2004
|
0.75
|
|
28
|
An analysis of teaching and coaching behaviors of elite strength and conditioning coaches.
|
J Strength Cond Res
|
2002
|
0.75
|
|
29
|
Interview with John Vincent, Ph.D.
|
Rejuvenation Res
|
2009
|
0.75
|
|
30
|
Differential Allelic Expression of HTR1B in Suicide Victims: Genetic and Epigenetic Effect of the Cis-Acting Variants.
|
Neuropsychobiology
|
2017
|
0.75
|
|
31
|
Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules.
|
Pharm Res
|
2011
|
0.75
|